ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2096

Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?

Marc Lambert1, Mohamed-Amine Oukili2, Cécile Yelnik3, Eric Hachulla1, Pierre-Yves Hatron1, Mehdi Djennaoui4 and Thomas Quémeneur2, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, 2Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 3Service de médecine interne, centre de référence des maladies systémiques et auto-immunes rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, 4Unité de biostatistiques, Hôpital de Valenciennes, Valenciennes, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Antiphospholipid syndrome and thrombosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Antiphospholipid Syndrome - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Risk of recurrence after a first episode of venous thrombo-embolism (VTE) is strongly correlated to VTE characteristics. Indefinite anticoagulation is recommended for patients with unprovoked VTE. VTE is the most frequent manifestation of antiphospholipid syndrome (APS). However a search for antiphospholipid antibodies (aPL) is not systematically performed after a provoked thrombosis. And although long-term anticoagulation is usually advised in APS, some authors have suggested stopping anticoagulation in provoked VTE. We aimed to determine the features of venous APS, according to the provoked or unprovoked nature of the first thrombotic event.

Methods:  We performed a retrospective study of patients who met Sidney criteria of APS, revealed by VTE. Provoked event was defined as major if VTE occurred < 12 weeks after surgery, after ≥ 3 days strict immobilization, or after lower-limb fracture and as minor if VTE occurred during travel, immobilisation, sepsis, oestrogen treatment or pregnancy. Other VTE were considered unprovoked.

Results: The files of 57 women and 30 men, with a mean age of 36.2 +/- 16.1 years were reviewed. VTE presented as: deep vein thrombosis (DVT) n= 46/87, pulmonary embolism +/- DVT n= 41/87. Laboratory exams revealed: lupus anticoagulant n = 67/87, triple positivity n = 38/87. VTE was provoked by major factors in 9 and minor factors in 36/87 patients. Pregnancy and oestrogens were involved in 29 cases. Mean follow-up was 121.7 +/- 73.1 months: 27 patients presented with one or more further thrombosis; the 1st recurrence was venous in 22 and arterial in 5/27 patients; 11/27 occured under anticoagulation. We found no correlation between clinical features and 1st recurrence. We observed one death related to catastrophic APS, and six major haemorrhages. In bivariate analysis, the unprovoked nature of VTE was associated with a higher age, male sex, dyslipidemia and past history of VTE. In multivariate analysis, we found no correlation between the nature of VTE and clinical or biological features at diagnosis or during follow-up.

Conclusion:  Provoking factors are frequent in venous APS. In this venous APS cohort with numerous high risk-profile patients, provoked nature of VTE was not correlated to clinical or biological features. A search for aPL should be advised in young patients with VTE even if thrombosis is provoked. This study does not support the hypothesis of a lower risk-profile of APS patients with provoked VTE.


Disclosure: M. Lambert, None; M. A. Oukili, None; C. Yelnik, None; E. Hachulla, None; P. Y. Hatron, None; M. Djennaoui, None; T. Quémeneur, None.

To cite this abstract in AMA style:

Lambert M, Oukili MA, Yelnik C, Hachulla E, Hatron PY, Djennaoui M, Quémeneur T. Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/venous-antiphospholipid-syndrome-is-the-unprovoked-nature-of-the-1st-thrombosis-associated-with-clinical-or-biological-features/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/venous-antiphospholipid-syndrome-is-the-unprovoked-nature-of-the-1st-thrombosis-associated-with-clinical-or-biological-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology